Paper29043232
Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia.
Yoon JH and 15 others. Blood Res, 2017. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia. Papers, record 29043232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29043232
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10502596 | Acute myeloid leukemia. | N Engl J Med | 1999 | https://conductscience.org/library/papers/10502596 | PubMed |
| 2 | 28089879 | Clinical Outcome of Autologous Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukemia: Who May Benefit from Autologous Hematopoietic Cell Transplantation? | Biol Blood Marrow Transplant | 2017 | https://conductscience.org/library/papers/28089879 | PubMed |
| 3 | 12393605 | Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. | Blood | 2003 | https://conductscience.org/library/papers/12393605 | PubMed |
| 4 | 8558199 | Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. | J Clin Oncol | 1996 | https://conductscience.org/library/papers/8558199 | PubMed |
| 5 | 20694843 | Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities. | Int J Hematol | 2010 | https://conductscience.org/library/papers/20694843 | PubMed |
| 6 | 25300871 | A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia. | Biol Blood Marrow Transplant | 2015 | https://conductscience.org/library/papers/25300871 | PubMed |
| 7 | 8078551 | Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. | N Engl J Med | 1994 | https://conductscience.org/library/papers/8078551 | PubMed |
| 8 | 20048183 | Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20048183 | PubMed |
| 9 | 8634416 | A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. | Blood | 1996 | https://conductscience.org/library/papers/8634416 | PubMed |
| 10 | 25833957 | A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. | Blood | 2015 | https://conductscience.org/library/papers/25833957 | PubMed |
| 11 | 26663264 | Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better? | Am J Hematol | 2016 | https://conductscience.org/library/papers/26663264 | PubMed |
| 12 | 9517503 | Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. | Leuk Lymphoma | 1998 | https://conductscience.org/library/papers/9517503 | PubMed |
| 13 | 22287757 | A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia. | Anticancer Res | 2012 | https://conductscience.org/library/papers/22287757 | PubMed |
| 14 | 21828126 | A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. | Blood | 2011 | https://conductscience.org/library/papers/21828126 | PubMed |
| 15 | 23398482 | Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. | Br J Haematol | 2013 | https://conductscience.org/library/papers/23398482 | PubMed |
| 16 | 15075074 | A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group. | Haematologica | 2004 | https://conductscience.org/library/papers/15075074 | PubMed |
| 17 | 3702507 | Phase I clinical and pharmacokinetic study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. | Med Oncol Tumor Pharmacother | 1986 | https://conductscience.org/library/papers/3702507 | PubMed |
| 18 | 8874180 | A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. | Blood | 1996 | https://conductscience.org/library/papers/8874180 | PubMed |
| 19 | 8916313 | Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study. | Semin Hematol | 1996 | https://conductscience.org/library/papers/8916313 | PubMed |
| 20 | 28687581 | Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2017 | https://conductscience.org/library/papers/28687581 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42583229 | Venetoclax plus azacitidine, low-dose cytarabine, aclarubicin, and G-CSF (VA-CAG regimen) for newly diagnosed young patients with acute myeloid leukemia: A prospective, multicenter, single-arm Phase II clinical trial. | Hemasphere | 2026 | https://conductscience.org/library/papers/42583229 | PubMed |
| 38023260 | Dynamic changes in physical function during intensive chemotherapy affect transplant outcomes in older adults with AML. | Front Oncol | 2023 | https://conductscience.org/library/papers/38023260 | PubMed |
| 37762881 | Machine Learning Predicts 30-Day Outcome among Acute Myeloid Leukemia Patients: A Single-Center, Retrospective, Cohort Study. | J Clin Med | 2023 | https://conductscience.org/library/papers/37762881 | PubMed |
| 36874817 | Effects of different psychological interventions on quality of life and remission rate in patients with acute leukemia receiving chemotherapy: A randomized controlled trial. | Front Psychol | 2023 | https://conductscience.org/library/papers/36874817 | PubMed |
| 29848341 | Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways. | J Hematol Oncol | 2018 | https://conductscience.org/library/papers/29848341 | PubMed |
Genes9
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BAALC | 79870 | PubTator's text mining | https://conductscience.org/library/genes/79870 | NCBI Gene |
| CD34 | 947 | PubTator's text mining | https://conductscience.org/library/genes/947 | NCBI Gene |
| CEBPA | 1050 | PubTator's text mining | https://conductscience.org/library/genes/1050 | NCBI Gene |
| CSF3 | 1440 | PubTator's text mining | https://conductscience.org/library/genes/1440 | NCBI Gene |
| DNMT3A | 1788 | PubTator's text mining | https://conductscience.org/library/genes/1788 | NCBI Gene |
| FLT3 | 2322 | PubTator's text mining | https://conductscience.org/library/genes/2322 | NCBI Gene |
| KIT | 3815 | PubTator's text mining | https://conductscience.org/library/genes/3815 | NCBI Gene |
| NPM1 | 4869 | PubTator's text mining | https://conductscience.org/library/genes/4869 | NCBI Gene |
| WT1 | 7490 | PubTator's text mining | https://conductscience.org/library/genes/7490 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29043232
GET https://conductscience.org/api/papers/v1/29043232/references?page=2